Etcamah (camizestrant) is an oral selective estrogen receptor degrader (SERD) and estrogen receptor antagonist indicated, in combination with a CDK4/6 inhibitor, for adults with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer with an ESR1 mutation detected during aromatase inhibitor and CDK4/6 inhibitor therapy.
Camizestrant works by binding to and degrading estrogen receptors, helping suppress estrogen-driven signaling involved in breast cancer growth. Etcamah provides a targeted treatment approach for ESR1-mutated breast cancer, where acquired resistance to endocrine therapy can become a significant challenge.
By directly targeting the estrogen receptor, it offers a differentiated strategy for maintaining disease control in patients whose tumors develop ESR1 mutations during treatment. Its approval expands the treatment landscape for biomarker-defined advanced breast cancer.
